Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS5315 in Rheumatoid Arthritis
NCT03605251Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TAS5315 in rheumatoid arthritis (RA), sponsored by Taiho Pharmaceutical Co., Ltd.. Started Aug 2018; status: completed.
02
Drugs
TAS5315
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03605251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605251.